PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Wednesday, July 3, 2013

An interesting case

Posted on 12:57 AM by Unknown

SAN DIEGO — A La Jolla oncologist was sentenced in San Diego federal court Tuesday to a year of probation, stemming from a scheme in which he and his practice treated patients with unapproved foreign cancer drugs, then fraudulently billed Medicare $1.7 million.

Dr. Joel I. Bernstein’s sentence is in addition to the one his medical corporation received Friday. His practice was ordered to pay a $500,000 fine, forfeit $1.2 million and make restitution to Medicare for $1.7 million.

The payments have all been paid, said his attorney, Charles Sevilla.

A federal judge also sentenced the practice to a year of probation, meaning officers can examine the company’s financial records at any time and submit to searches.

The case is one of many being investigated by the FDA that highlights the controversy over the pricing of pharmaceuticals in the U.S. and the cost of medical care.

More than two dozen of Bernstein’s patients and their caregivers packed into the courtroom Tuesday in support of the doctor.

“Doctors are trapped as an economic result of ‘big pharma,’” Dan Hentschke, whose wife was successfully treated by Bernstein, said outside the courtroom. “This was an economic crime, this wasn’t a treatment crime.”

Bernstein’s practice admitted to buying $3.4 million of foreign cancer drugs from 2007 to 2011 at significant discounts when compared to similar medicine approved by the U.S. Food and Drug Administration.

The office then submitted claims to Medicare for the drugs, using codes for similar approved cancer drugs. The insurance program for seniors and the disabled does not pay for non-FDA approved medicines.

The foreign drugs have the same active ingredients as those sold in the U.S., including brand names Boniva, Alimta and Eloxatin.

The doctor’s practice received $1.7 million from Medicare, and earned another $1.2 million in gross proceeds related to the drugs, according to court documents.

Bernstein himself pleaded guilty to a misdemeanor charge of introducing unapproved drugs into interstate commerce, admitting to buying the prescription drug Mabthera from Canada. The drug is intended to be used in Turkey, not the U.S.

Prosecutors said Bernstein and his office were well aware the drugs were not approved by the FDA, as evidenced by shipping labels from the United Kingdom, differences in the labeling and a 2008 warning letter from the FDA that a shipment of drugs had been confiscated. His attorneys have said there is no evidence his patients were harmed by the drugs.

The practice and Bernstein pleaded guilty to the scheme in January.

In addition to the criminal cases, the doctor and his practice paid $2.2 million to settle a civil False Claims Act lawsuit. That amount is being applied toward the restitution owed to Medicare, the U.S. Attorney’s Office said.

Bernstein, who went to medical school at Stanford University, declined to make a statement in court, saying his attorney had already spoken for him.

Prosecutors have not asked that his medical license be revoked, saying it is up to the California Medical Board. Bernstein has been a board certified physician since 1980 and has no other disciplinary actions, according to the board.

http://www.utsandiego.com/news/2013/jul/02/cancer-drug-FDA-bernstein-doctor-la-jolla/?

Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ►  August (70)
    • ▼  July (104)
      • Still a fantastic read
      • GlaxoChinaGate contd. - Nothing uniquely Chinese a...
      • Hope for the future
      • Slumdog clinical trials contd. - BMJ editorial: In...
      • Let the sunshine in
      • Hongbao - the red envelope
      • Sharing data from clinical trials: where we are an...
      • Pfizer Pleads Guilty, Pays $491 Million Over Rapam...
      • Caveat lector!
      • Now this is worrying
      • FDA toughens malaria drug labeling because sometim...
      • An addiction that is hard to break
      • GlaxoChinaGate contd. The case of Zhao Hongyan, th...
      • Perrigo buys Irish drug maker Elan in $8.6bn deal
      • 1boringoldman makes the case for data transparency
      • GSK investigation reveals something rotten - China...
      • The Glaxo-China Bribery Scandal: A New Policeman W...
      • UK pharma shows signs of dangerous addiction
      • Paul Krugman: China’s economy has hit its Great Wall
      • Class-action suit over Pfizer Canada's anti-smokin...
      • GlaxoChinaGate contd. - Reilly to return to China!
      • China state media says 18 more detained in GSK probe
      • Bergstroem's mobilising memo
      • GlaxoChinaGate contd.- The World of Suzie Wang
      • GlaxoChinaGate contd. - is this the payoff?
      • Big Pharma’s data sharing principles “weak and fil...
      • GlaxoChinaGate contd. - the Chinese police reveal ...
      • Banks and Big Pharmas hire private eyes who break ...
      • Pharma industry downplays lobbyism with patient gr...
      • Meanwhile, in other GSK news...
      • GlaxoChinaGate contd. Witty may not be forthcoming...
      • The World According to Monsanto
      • Patient groups commit to transparency after leaked...
      • GSK's China crisis: questions for Witty that need ...
      • More Astra staff held in China as GSK crisis deepens
      • Antimalarial Drug Linked to Sgt. Robert Bales Mass...
      • Drug Research in China Falls Under a Cloud
      • How to lower Big Pharma's drug prices the Chinese way
      • It's a strange old world
      • A message from AllTrials.net
      • GSK's China Crisis spreads
      • Files Suggest a Graft Case in China May Expand - NYT
      • AllTrials contd. Which patient groups are in Big P...
      • Healthcare in China: GSK claims prompt crackdown o...
      • More on Peter Humphrey, MD of ChinaWhys
      • GSK boss to address China scandal at quarterly res...
      • Killing the chicken to scare the monkey
      • GlaxoSmithKline briefs Serious Fraud Office over C...
      • Comment: China crisis growing for troubled Glaxo
      • China - getting in is easier than getting out!
      • GlaxoSmithKline's China crisis: why it changes the...
      • GlaxoSmithKline rushes executives to China to hand...
      • GSK chief Andrew Witty set to admit China 'scam’
      • Can Merck Finally Get Past the Vioxx Scandal?
      • NHS could save £84m using cheaper drug to prevent ...
      • Worth every penny
      • China - Now UCB get a visit
      • Johnson and Johnson Settles Suit Alleging Manageme...
      • GSK China's General Manager Mark Reilly Presents O...
      • Pharma Companies Must End Secret Gifts To Doctors ...
      • Eli Lilly to Freeze Employee Base Pay Ahead of Gen...
      • Latest MTRAC reviews
      • China bars Glaxo finance director from leaving cou...
      • GSK's Andrew Witty's new role in China
      • Four Drugmakers Face China Probes as Glaxo Woes Widen
      • A fish starts to rot from the head. After GSK, who...
      • Sexual Favors Spur Glaxo’s $1.5 Billion China Sale...
      • First GSK denied......
      • GSK China - Watch the confession
      • Anyone know where GSK's Mark Reilly is?
      • AZ - Exit the gas man
      • Do Clinical Trials Work? - NYT
      • David Healy vs AbbVie - A good medicine is a chemi...
      • UK NHS hit for millions by overcharging ‘scam’ - ...
      • Chinese clinical trials probed
      • Did Big Pharma team up to kill British Columbia's ...
      • Japan vows action over claims of fabricated drug data
      • Stopping Big Pharma From Using New .pharmacy Domai...
      • Our medical schools must not become shills for big...
      • GSK vs PSB
      • China security ministry says GSK executives confes...
      • Merck 'Evergreens' Off-Patent Lipitor By Creating ...
      • Wolfe Attack!
      • Drug Rep$
      • Are Clinical Trial Data Shared Sufficiently Today?
      • Stop blanket animal antibiotics now - before it's ...
      • Castellani vs Goldacre
      • Recent €23 Million Biotech IPO Relied Heavily On Q...
      • Australia targets Nurofen
      • New bribery allegations hit GlaxoSmithKline in China:
      • GSK's Dierdre P. Connelly makes a promise
      • Gouging contd. - How to make a $300 drug cost $30,...
      • "It may have been Roaccutane"
      • Ghost- and Guest-Authored Pharmaceutical Industry-...
      • Drs. Oz & Roizen's Tip of the Day: What's up with ...
      • Tchotchke War Looms
      • Ten tips when writing about clinical trials by Rut...
      • Pfizer and Merck
      • An interesting case
      • Pharma "a prime target" of govt health cuts in 201...
      • Sanofi to cut 207 R&D jobs in latest French reshuffle
      • Clot Wars contd.
      • GlaxoSmithKline Probe in China Follows Drug Safety...
      • Merck's Mess
    • ►  June (81)
    • ►  May (5)
Powered by Blogger.